Evidence map›Paper›PMID 26282581›Full record

ArticleThe Journal of physiology2015

GABAB receptor-mediated feed-forward circuit dysfunction in the mouse model of fragile X syndrome.

Sarah Wahlstrom-Helgren, Vitaly A Klyachko

3 registry-linked trialsAbstract read
In one paragraph

Article in The Journal of physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06480968 phase1completednot on this mapstarted 2023, after this paper: background citation

Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2023 to 2024Enrolled76ConditionsFragile X SyndromeArmsCTH120, Placebo
NCT06957054 completednot on this mapstarted 2024, after this paper: background citation

Assessment of Neural Biomarkers in Adult Subjects With Fragile X Syndrome and Typically Developing Subjects

TypeobservationalSponsorConnecta Therapeutics, S.L.Ran2024 to 2025Enrolled20ConditionsFragile X Syndrome (FXS), Neurotypical AdultsArmsAny
NCT07654114 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2026 to 2027Enrolled30ConditionsFragile X Syndrome (FXS), Fragile X SyndromeArmsCTH120, CTH120 placebo hard capsules
3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Altered brain serotonin 5-HTNeuropharmacology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Keeping the Balance: GABABrain sciences · 2022
    Review
  11. GABACurrent topics in behavioral neurosciences · 2022
    Review
  12. Article
  13. Channelopathies in fragile X syndrome.Nature reviews. Neuroscience · 2021
    Review
  14. Review
  15. Hyperexcitability and Homeostasis in Fragile X Syndrome.Frontiers in molecular neuroscience · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Of Men and Mice: Modeling the Fragile X Syndrome.Frontiers in molecular neuroscience · 2018
    Article
  20. New Insights Into the Role of CaFrontiers in molecular neuroscience · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sarah Wahlstrom-HelgrenDepartments of Cell Biology and Physiology, Biomedical Engineering, Center for the Investigation of Membrane Excitable Diseases, Washington University School of Medicine, St Louis, MO, 63110, USA.
Vitaly A KlyachkoDepartments of Cell Biology and Physiology, Biomedical Engineering, Center for the Investigation of Membrane Excitable Diseases, Washington University School of Medicine, St Louis, MO, 63110, USA.

Funding

MULTIPLE ROLES OF FMRP IN SYNAPTIC FUNCTION AND PLASTICITYR01NS081972 · NINDS · WASHINGTON UNIVERSITY · PI KLYACHKO, VITALY A · 2012 to 2016
$1.7M
NINDS NIH HHS R01 NS081972PHS HHS 091809/Z/10/Z
6 · The paper itself

Abstract

key pointsCortico-hippocampal feed-forward circuits formed by the temporoammonic (TA) pathway exhibit a marked increase in excitation/inhibition ratio and abnormal spike modulation functions in Fmr1 knock-out (KO) mice. Inhibitory, but not excitatory, synapse dysfunction underlies cortico-hippocampal feed-forward circuit abnormalities in Fmr1 KO mice. GABA release is reduced in TA-associated inhibitory synapses of Fmr1 KO mice in a GABAB receptor-dependent manner. Inhibitory synapse and feed-forward circuit defects are mediated predominately by presynaptic GABAB receptor signalling in the TA pathway of Fmr1 KO mice. GABAB receptor-mediated inhibitory synapse defects are circuit-specific and are not observed in the Schaffer collateral pathway-associated inhibitory synapses in stratum radiatum. ABSTRACT: Circuit hyperexcitability has been implicated in neuropathology of fragile X syndrome, the most common inheritable cause of intellectual disability. Yet, how canonical unitary circuits are affected in this disorder remains poorly understood. Here, we examined this question in the context of the canonical feed-forward inhibitory circuit formed by the temporoammonic (TA) branch of the perforant path, the major cortical input to the hippocampus. TA feed-forward circuits exhibited a marked increase in excitation/inhibition ratio and major functional defects in spike modulation tasks in Fmr1 knock-out (KO) mice, a fragile X mouse model. Changes in feed-forward circuits were caused specifically by inhibitory, but not excitatory, synapse defects. TA-associated inhibitory synapses exhibited increase in paired-pulse ratio and in the coefficient of variation of IPSPs, consistent with decreased GABA release probability. TA-associated inhibitory synaptic transmission in Fmr1 KO mice was also more sensitive to inhibition of GABAB receptors, suggesting an increase in presynaptic GABAB receptor (GABAB R) signalling. Indeed, the differences in inhibitory synaptic transmission between Fmr1 KO and wild-type (WT) mice were eliminated by a GABAB R antagonist. Inhibition of GABAB Rs or selective activation of presynaptic GABAB Rs also abolished the differences in the TA feed-forward circuit properties between Fmr1 KO and WT mice. These GABAB R-mediated defects were circuit-specific and were not observed in the Schaffer collateral pathway-associated inhibitory synapses. Our results suggest that the inhibitory synapse dysfunction in the cortico-hippocampal pathway of Fmr1 KO mice causes hyperexcitability and feed-forward circuit defects, which are mediated in part by a presynaptic GABAB R-dependent reduction in GABA release.

Indexed as

Inhibitory Postsynaptic PotentialsAnimalsCerebral CortexFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeMiceReceptors, GABA-BSynapsesThalamusFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1Receptors, GABA-B

Identifiers

PMID26282581
PMCPMC4650406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.